You need to enable JavaScript to run this app.
Recon: Moderna starts Phase 2 hybrid study aimed at Omicron, FDA steps up use of CRLs for breakthrough drugs
Recon
Joanne S. Eglovitch
Global
ReconJoanne S. Eglovitch
GlobalReconJoanne S. EglovitchGlobal